Antihypertensive spirapril effectiveness in patients with mild to moderate arterial hypertension
Aim. То study 12-week spirapril (Quadropril®) therapy effectiveness in patients with mild to moderate arterial hypertension (АП). Material and metliods. For 12 weeks, 62 patients with mild to moderate АП received spirapril (6 mg/d), with diuretics (hydrochlorthiazide or Arifon retard) added if antih...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«SILICEA-POLIGRAF» LLC
1970-01-01
|
Series: | Кардиоваскулярная терапия и профилактика |
Subjects: | |
Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1527 |
Summary: | Aim. То study 12-week spirapril (Quadropril®) therapy effectiveness in patients with mild to moderate arterial hypertension (АП). Material and metliods. For 12 weeks, 62 patients with mild to moderate АП received spirapril (6 mg/d), with diuretics (hydrochlorthiazide or Arifon retard) added if antihypertensive effect was insufficient. Results. Blood pressure (BP) normalized in 25,8% of the patients. Adding diuretics (hydrochlorthiazide, 25 mg/d, or Arifon® retard, 1,5 mg/d) normalized BP in the rest of the participants. Circadian BP rhythm was also normalized. Spirapril was well tolerated by the patients. Conclusion. ACE inhibitor spirapril (Quadropril®) effectively normalizes BP in patients with mild to moderate АП. In case of insufficient antihypertensive effect, combination with diuretics allows to normalize BP in extra 87% of the patients. |
---|---|
ISSN: | 1728-8800 2619-0125 |